Quantitative determination of buprenorphine and its active metabolite, norbuprenorphine, in human plasma by gas chromatography—chemical ionization mass spectrometry

Ohtani, Michiteru; Shibuya, Fuminori; Kotaki, Hajime; Uchino, Katsuyoshi; Saitoh, Yurika; Nakagawa, Fujio; Nishitateno, Kenji

doi:10.1016/s0378-4347(00)83057-1

Cited by 26 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A factor that is worth mentioning in the present context is the N-dealkyl metabolite of buprenorphine, norbuprenorphine, which is the major metabolite of buprenorphine in humans and rats (Cone et al 1985;Ohtani et al 1989Ohtani et al , 1995. Norbuprenorphine might contribute to the effects and side-effects produced by buprenorphine administration (Ohtani et al 1995(Ohtani et al , 1997.…”

Section: Antagonism Of Buprenorphine Cpp Effectsmentioning

confidence: 99%

Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations

Tzschentke

2004

Psychopharmacology

View full text Add to dashboard Cite

The present results suggest that the reported lack of CPP effects at high doses of buprenorphine may be due to factors in the experimental design, resulting in a carry-over effect from drug- to vehicle conditioning. They also suggest that buprenorphine, like other opiates, produces its CPP effects via micro -receptors, although kappa-antagonistic mechanisms also appear to be involved. The implications of these findings for the safety of buprenorphine for human use are discussed.

show abstract

Section: Antagonism Of Buprenorphine Cpp Effectsmentioning

confidence: 99%

Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations

Tzschentke

2004

Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Analytical methods for urine [7–13], plasma [8, 10, 14–18], oral fluid [19], hair [13, 20, 21], and feces [12] have been published. To date, enzyme or acidic hydrolysis of buprenorphine and norbuprenorphine glucuronides has been necessary prior to GC testing [7, 9].…”

Section: Introductionmentioning

confidence: 99%

Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in human placenta by liquid chromatography mass spectrometry

2009

View full text Add to dashboard Cite

A LCMS method was developed and validated for the determination of buprenorphine (BUP), norbuprenorphine (NBUP), buprenorphine glucuronide (BUP-Gluc), and norbuprenorphine glucuronide (NBUP-Gluc) in placenta. Quantification was achieved by selected ion monitoring of m/z 468.4 (BUP), 414.3 (NBUP), 644.4 (BUP-Gluc), and 590 (NBUP-Gluc). BUP and NBUP were identified monitoring MS2 fragments m/z 396, 414 and 426 for BUP, and 340, 364 and 382 for NBUP, and glucuronide conjugates monitoring MS3 fragments m/z 396 and 414 for BUP-Gluc, and 340 and 382 for NBUP-Gluc. Linearity was 1–50 ng/g. Intra-day, inter-day and total assay imprecision (% RSD) were <13.4%, and analytical recoveries were 96.2–113.1%. Extraction efficiencies ranged from 40.7–68%, process efficiencies 38.8–70.5%, and matrix effect 1.3–15.4%. Limits of detection were 0.8 ng/g for all compounds. An authentic placenta from an opioid-dependent pregnant woman receiving BUP pharmacotherapy was analyzed. BUP was not detected but metabolite concentrations were NBUP-Gluc 46.6, NBUP 15.7 and BUP-Gluc 3.2 ng/g.

show abstract

“…Numerous methods have been published for the determination of Bu and norBu in biological matrices including immunoassays [3][4][5][6]; gas chromatography with electron capture detection (GC-ECD) [7,8]; liquid chromatography (LC) with electrochemical detection [9][10][11]; LC with fluorescence detection [12]; a variety of mass spectrometric (MS) methods which includes GC-MS [13][14][15][16], LC-MS [17][18][19][20] and LC-MS/MS [21][22][23][24][25].…”

Section: Introductionmentioning

confidence: 99%

Simultaneous determination of buprenorphine, norbuprenorphine and the enantiomers of methadone and its metabolite (EDDP) in human plasma by liquid chromatography/mass spectrometry

Rodriguezrosas

Lofwall

Strain

et al. 2007

Journal of Chromatography B

View full text Add to dashboard Cite

Quantitative determination of buprenorphine and its active metabolite, norbuprenorphine, in human plasma by gas chromatography—chemical ionization mass spectrometry

Cited by 26 publications

References 9 publications

Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations

Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations

Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in human placenta by liquid chromatography mass spectrometry

Simultaneous determination of buprenorphine, norbuprenorphine and the enantiomers of methadone and its metabolite (EDDP) in human plasma by liquid chromatography/mass spectrometry

Contact Info

Product

Resources

About